TENX

Tenax Therapeutics (TENX)

Tenax Therapeutics Inc

일자:

규정 관련뉴스

텍스트 검색:

정렬 기준:

규정 외 뉴스

검색 관련기사 보기:NASDAQ:TENX

1 2 3 4 5 6 7 8 9 10 다음 >>

일자	시간	출처	헤드라인	심볼	기업
2024/05/15	05:01	Edgar (US Regulatory)	Form 10-Q - Quarterly report [Sections 13 or 15(d)]	NASDAQ:TENX	Tenax Therapeutics Inc
2024/05/14	22:01	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:TENX	Tenax Therapeutics Inc
2024/05/14	21:00	GlobeNewswire Inc.	Tenax Therapeutics Reports First Quarter 2024 Financial Results and Provides a Corporate Update	NASDAQ:TENX	Tenax Therapeutics Inc
2024/04/30	20:30	GlobeNewswire Inc.	Tenax Therapeutics Announces New U.S. Patent Covering the Use of Levosimendan in Pulmonary Hypertension with Heart Failure with Preserved Ejection Fraction (PH-HFpEF)	NASDAQ:TENX	Tenax Therapeutics Inc
2024/04/09	21:30	GlobeNewswire Inc.	Tenax Therapeutics to Host KOL Event: “LEVEL Setting: the Scientific Rationale for Levosimendan as a Potential First Treatment for PH-HFpEF, and the Ongoing Phase 3 LEVEL Study”	NASDAQ:TENX	Tenax Therapeutics Inc
2024/03/28	21:30	GlobeNewswire Inc.	Tenax Therapeutics Provides Business and Clinical Development Updates with Full Year 2023 Financial Results	NASDAQ:TENX	Tenax Therapeutics Inc
2024/03/12	21:30	GlobeNewswire Inc.	Tenax Therapeutics to Present at the 36th Annual Roth Conference	NASDAQ:TENX	Tenax Therapeutics Inc
2024/02/29	23:00	GlobeNewswire Inc.	Tenax Therapeutics Announces Oral Presentation of Levosimendan for the Treatment of PH-HFpEF at THT 2024	NASDAQ:TENX	Tenax Therapeutics Inc
2024/02/27	06:31	Edgar (US Regulatory)	Form 424B3 - Prospectus [Rule 424(b)(3)]	NASDAQ:TENX	Tenax Therapeutics Inc
2024/02/27	06:31	Edgar (US Regulatory)	Form 424B3 - Prospectus [Rule 424(b)(3)]	NASDAQ:TENX	Tenax Therapeutics Inc
2024/02/24	06:30	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:TENX	Tenax Therapeutics Inc
2024/02/22	06:32	Edgar (US Regulatory)	Form 424B3 - Prospectus [Rule 424(b)(3)]	NASDAQ:TENX	Tenax Therapeutics Inc
2024/02/22	06:30	Edgar (US Regulatory)	Form 424B3 - Prospectus [Rule 424(b)(3)]	NASDAQ:TENX	Tenax Therapeutics Inc
2024/02/21	06:01	Edgar (US Regulatory)	Form SC 13G - Statement of acquisition of beneficial ownership by individuals	NASDAQ:TENX	Tenax Therapeutics Inc
2024/02/20	22:33	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:TENX	Tenax Therapeutics Inc
2024/02/20	22:30	GlobeNewswire Inc.	Tenax Therapeutics Announces Global License Amendment that Significantly Expands Rights to Levosimendan	NASDAQ:TENX	Tenax Therapeutics Inc
2024/02/17	01:28	Edgar (US Regulatory)	Form SC 13G - Statement of acquisition of beneficial ownership by individuals	NASDAQ:TENX	Tenax Therapeutics Inc
2024/02/16	09:36	Edgar (US Regulatory)	Form SC 13G - Statement of acquisition of beneficial ownership by individuals	NASDAQ:TENX	Tenax Therapeutics Inc
2024/02/15	04:58	Edgar (US Regulatory)	Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]	NASDAQ:TENX	Tenax Therapeutics Inc
2024/02/14	06:32	Edgar (US Regulatory)	Form 424B3 - Prospectus [Rule 424(b)(3)]	NASDAQ:TENX	Tenax Therapeutics Inc
2024/02/13	06:46	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:TENX	Tenax Therapeutics Inc
2024/02/10	07:00	Edgar (US Regulatory)	Form 424B4 - Prospectus [Rule 424(b)(4)]	NASDAQ:TENX	Tenax Therapeutics Inc
2024/02/09	06:51	Edgar (US Regulatory)	Form 424B3 - Prospectus [Rule 424(b)(3)]	NASDAQ:TENX	Tenax Therapeutics Inc
2024/02/08	22:16	GlobeNewswire Inc.	Tenax Therapeutics Announces Pricing of Approximately $9 Million Public Offering	NASDAQ:TENX	Tenax Therapeutics Inc
2024/02/08	14:15	Edgar (US Regulatory)	Form EFFECT - Notice of Effectiveness	NASDAQ:TENX	Tenax Therapeutics Inc
2024/02/08	10:01	GlobeNewswire Inc.	Tenax Therapeutics Enrolls First Patient in Phase 3 LEVEL Study Evaluating TNX-103 (Oral Levosimendan) for the Treatment of Pulmonary Hypertension in Heart Failure with Preserved Ejection Fraction (PH-HFpEF)	NASDAQ:TENX	Tenax Therapeutics Inc
2024/02/06	23:20	Edgar (US Regulatory)	Form 424B3 - Prospectus [Rule 424(b)(3)]	NASDAQ:TENX	Tenax Therapeutics Inc
2024/02/06	22:56	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:TENX	Tenax Therapeutics Inc
2024/02/06	22:30	GlobeNewswire Inc.	Tenax Therapeutics Announces USPTO Grants Notice of Allowance for U.S. Patent Application, Significantly Broadening IP Protection for Use of Levosimendan in Pulmonary Hypertension with Heart Failure with Preserved Ejection Fraction (PH-HFpEF)	NASDAQ:TENX	Tenax Therapeutics Inc
2024/02/03	07:24	Edgar (US Regulatory)	Form S-1/A - General form for registration of securities under the Securities Act of 1933: [Amend]	NASDAQ:TENX	Tenax Therapeutics Inc